Question 110 — diseases

Summary

Mr. Arnaud Viala questions the Minister of Solidarity and Health on the situation of multiple myeloma patients. Multiple myeloma refers to a form of bone marrow cancer which affects thousands of French people and whose number of patients is constantly increasing. There are nearly 5,000 new cases each year, in addition to the 30,000 people already affected. Myeloma is a disease that aspires to become chronic with successive phases of remission and relapse. It is therefore necessary for the patient to benefit from effective and appropriate treatment over time to ensure their survival, and to guarantee them autonomy and a dignified quality of life for as long as possible. Innovative drugs have been authorized in France, rekindling a glimmer of hope among patients. However, the availability of these treatments is enormously complex, adding stress and worry to people who suffer sufficiently from their illness. They don't need to be more concerned, just about being able to access treatment. Carfilzomib represents therapeutic progress in patient care. This medication, which meets all the conditions to be included on the so-called “extra” list allowing reimbursement to hospitals by health insurance is still not available to patients, due to a purely administrative blockage. However, access to this treatment is necessary for thousands of patients. It is not acceptable for a patient suffering from a serious illness to know that a medication that gives them a chance of survival exists, but to see their state of health deteriorate because they cannot benefit from the treatment because of the dysfunction of administrations linked to the failure to cover these new drugs. He asks what measures the Government intends to take to make these medicines accessible.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.